A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
Conclusion
The rapid change of the treatment landscape, the limited use of BEV/IFN in 1st line and the durati on of 1st line treatment jeopardized BERAT trial recruitment. The small number of patients is a major limitation of our trial. Our observation indicated the poor prognosis in progressive patients and the limited efficacy of TKI or mTOR inhbitors in 2nd line treatment. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 19, 2022 Category: Cancer & Oncology Source Type: research
Bone Infarct Associated Osteosarcoma: Epidemiologic and Survival Trends
Conclusions Based on this work, our opinion is that the choice to undergo the patients to ChT combined to surgery could improve their prognosis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 14, 2022 Category: Cancer & Oncology Source Type: research
Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated With Concurrent Chemoradiation: A Multicenter Study
In this study, we analyzed the efficacy of AC after CCRT in stage III CC patients.
Methods: We performed a multicenter, retrospective analysis of 139 FIGO stage III CC patients treated with CCRT of whom 45.3% received AC. Our goal was to determine the impact of AC on survival in these patients.
Results: Five-year progression-free survival was 37.5% and 16% in patients receiving CCRT with and without AC, respectively (p=0.008). Median PFS was 30.9 months (CI 95 %14.8-46.9) and 16.6 months (CI 95% 9.3-23.9) in patients receiving CCRT with and without AC, respectively. Five-year overall survival was 78.2% and 28.4% in patie...
Source: Oncology Research and Treatment - January 14, 2022 Category: Cancer & Oncology Source Type: research
Preliminary Clinical Validation of a Filtration-Based CTC Assay for Tumor Burden and HER2 Status Monitoring in Metastatic Breast Cancer
Conclusion: The preliminary results from this study suggest promise for the interrogated CDC assay in several aspects, including sensitive CTC detection, accurate disease status reflection, and HER2 status determination. More studies are warranted to validate these findings and further characterize the value of CTC assay.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 11, 2022 Category: Cancer & Oncology Source Type: research
Risk and Prognosis of Subsequent Primary Gastric Cancer
Introduction: The incidence and prognostic impact of subsequent primary gastric cancer (GC) in a population of other cancer survivors is unclear. We aimed to evaluate susceptibility to subsequent primary GC in cancer survivors and prognosis of GC with prior cancer history.
Methods: 2,211 and 23,416 GC cases with and without prior cancer history were retrospectively selected from the Surveillance, Epidemiology and End Results (SEER) database. Potential risk of developing subsequent primary GC was assessed through standardized incidence ratios (SIRs). Cox regression were adopted to analyze the influence of prior cancer hist...
Source: Oncology Research and Treatment - January 9, 2022 Category: Cancer & Oncology Source Type: research
Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach
Background Management of Raswild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge. Development of treatment resistance with prevalence of pre-existing RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques.
Summary The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the ...
Source: Oncology Research and Treatment - January 9, 2022 Category: Cancer & Oncology Source Type: research
The Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients
Background: Breast cancer is still the most common malignancy in women worldwide. Once metastasized, breast cancer treatment primarily aims at reducing symptom burden, thereby trying to maintain and improve a patient ´s quality of life (QoL), delaying disease progression, and prolonging survival. Curing the disease is not possible in the palliative setting. To better understand metastatic breast cancer patients, their symptoms and wishes, which are important for treatment-decision making and outcome, patient-re ported outcomes (PROs) are of great importance, giving an impression of what really matters to and concerns a pa...
Source: Oncology Research and Treatment - January 9, 2022 Category: Cancer & Oncology Source Type: research
Supportive Care Needs and the Impact of Loss of Functioning and Symptom Burden on the Quality of Life in Patients with Advanced Colorectal Cancer
Conclusions Significant links between CRC-related loss of functioning, symptom burden, QoL and supportive care needs have been established. Longitudinal studies are planned to clarify cause-and-effects relationships and establish sequences of events. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 4, 2022 Category: Cancer & Oncology Source Type: research
The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Conclusion: The boron-based gel has a significant preventive effect on several categories of RD which might be used by clinicians in breast cancer.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 3, 2022 Category: Cancer & Oncology Source Type: research
Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study
Introduction: Cancer-associated venous thrombosis (CAT) is a common and serious complication of active malignancies, increasing in frequency during systemic treatment and radiotherapy. Due to a high risk of recurrence and bleeding, the administration of anticoagulants for initial treatment and secondary prevention of CAT is challenging. We conducted a prospective registry study of patients with acute CAT to evaluate the way treatment is given to these patients in routine practice.
Methods: From May 2015 to May 2017, all consecutive patients with acute venous thromboembolism (VTE) admitted to specialty or emergency departm...
Source: Oncology Research and Treatment - December 28, 2021 Category: Cancer & Oncology Source Type: research
Antibody-Drug Conjugates for Breast Cancer
Background: Despite the advances that have been made to improve conventional chemotherapies, their use is limited by a narrow therapeutic window based on off-target toxicities. Antibody-drug conjugates (ADCs) are composed of an antibody and a toxic payload covalently coupled by a chemical linker. They constitute an elegant means to tackle the limitations of conventional chemotherapeutics by selectively delivering a highly toxic payload directly to target cells and thereby increasing efficacy of the delivered cytotoxic but at the same time limiting systemic exposure and toxicities. As such, they appear inspired by Paul Ehrl...
Source: Oncology Research and Treatment - December 16, 2021 Category: Cancer & Oncology Source Type: research
Antibody-Drug-Conjugates for Breast Cancer
Background
Despite the advances that have been made to improve conventional chemotherapies, their use is limited by a narrow therapeutic window based on off-target toxicities.
Antibody-drug-conjugates (ADCs) are composed of an antibody and a toxic payload covalently coupled by a chemical linker. They constitute an elegant means to tackle the limitations of conventional chemotherapeutics by selectively delivering a highly toxic payload directly to target cells and thereby increasing efficacy of the delivered cytotoxic but at the same time limiting systemic exposure and toxicities. As such they appear inspired by Paul Ehrl...
Source: Oncology Research and Treatment - December 16, 2021 Category: Cancer & Oncology Source Type: research
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin and Docetaxel within the CEFCID Trial
Conclusion: Therapy intensification not adversely affect selected scores of QoL of patients with recurrent and/or metastatic SCCHN. Nevertheless, fatigue seems to be pronounced in patients treated with docetaxel. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 10, 2021 Category: Cancer & Oncology Source Type: research
New Opportunities in Advanced Breast Cancer
n/a (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 10, 2021 Category: Cancer & Oncology Source Type: research
Erratum
Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 10, 2021 Category: Cancer & Oncology Source Type: research
